Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells generic active pharmaceutical ingredients (APIs) and formulations in India, the United States, Europe, and internationally..
Flawless balance sheet with proven track record.
Share Price & News
How has Shilpa Medicare's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SHILPAMED's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: SHILPAMED exceeded the Indian Pharmaceuticals industry which returned 28.1% over the past year.
Return vs Market: SHILPAMED exceeded the Indian Market which returned -5.4% over the past year.
Price Volatility Vs. Market
How volatile is Shilpa Medicare's share price compared to the market and industry in the last 5 years?
Simply Wall St News
22 hours ago | Simply Wall StShilpa Medicare Limited's (NSE:SHILPAMED) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
2 weeks ago | Simply Wall StShilpa Medicare (NSE:SHILPAMED) Seems To Use Debt Quite Sensibly
1 month ago | Simply Wall StWhat Is Shilpa Medicare's (NSE:SHILPAMED) P/E Ratio After Its Share Price Rocketed?
Is Shilpa Medicare undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: SHILPAMED (₹508.75) is trading above our estimate of fair value (₹17.14)
Significantly Below Fair Value: SHILPAMED is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: SHILPAMED is poor value based on its PE Ratio (26.5x) compared to the IN Pharmaceuticals industry average (18.2x).
PE vs Market: SHILPAMED is poor value based on its PE Ratio (26.5x) compared to the Indian market (12.6x).
Price to Earnings Growth Ratio
PEG Ratio: SHILPAMED is poor value based on its PEG Ratio (1.4x)
Price to Book Ratio
PB vs Industry: SHILPAMED is overvalued based on its PB Ratio (3.1x) compared to the IN Pharmaceuticals industry average (1.6x).
How is Shilpa Medicare forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SHILPAMED's forecast earnings growth (18.8% per year) is above the savings rate (7.2%).
Earnings vs Market: SHILPAMED's earnings (18.8% per year) are forecast to grow slower than the Indian market (18.9% per year).
High Growth Earnings: SHILPAMED's earnings are forecast to grow, but not significantly.
Revenue vs Market: SHILPAMED's revenue (14.1% per year) is forecast to grow faster than the Indian market (7.3% per year).
High Growth Revenue: SHILPAMED's revenue (14.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SHILPAMED's Return on Equity is forecast to be low in 3 years time (14.1%).
How has Shilpa Medicare performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SHILPAMED has a high level of non-cash earnings.
Growing Profit Margin: SHILPAMED's current net profit margins (17.2%) are higher than last year (15.3%).
Past Earnings Growth Analysis
Earnings Trend: SHILPAMED's earnings have grown by 9.1% per year over the past 5 years.
Accelerating Growth: SHILPAMED's earnings growth over the past year (39.3%) exceeds its 5-year average (9.1% per year).
Earnings vs Industry: SHILPAMED earnings growth over the past year (39.3%) exceeded the Pharmaceuticals industry 18.6%.
Return on Equity
High ROE: SHILPAMED's Return on Equity (11.7%) is considered low.
How is Shilpa Medicare's financial position?
Financial Position Analysis
Short Term Liabilities: SHILPAMED's short term assets (₹6.2B) exceed its short term liabilities (₹4.1B).
Long Term Liabilities: SHILPAMED's short term assets (₹6.2B) exceed its long term liabilities (₹2.6B).
Debt to Equity History and Analysis
Debt Level: SHILPAMED's debt to equity ratio (25%) is considered satisfactory.
Reducing Debt: SHILPAMED's debt to equity ratio has reduced from 34.4% to 25% over the past 5 years.
Debt Coverage: SHILPAMED's debt is well covered by operating cash flow (37.5%).
Interest Coverage: SHILPAMED's interest payments on its debt are well covered by EBIT (38.6x coverage).
What is Shilpa Medicare current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: SHILPAMED's dividend (0.22%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.69%).
High Dividend: SHILPAMED's dividend (0.22%) is low compared to the top 25% of dividend payers in the Indian market (2.73%).
Stability and Growth of Payments
Stable Dividend: SHILPAMED is not paying a notable dividend for the Indian market, therefore no need to check if payments are stable.
Growing Dividend: SHILPAMED is not paying a notable dividend for the Indian market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: SHILPAMED is not paying a notable dividend for the Indian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SHILPAMED's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Vishnukanth Bhutada (58yo)
Mr. Vishnukanth Chaturbhuj Bhutada, B. Pharm. serves as the Managing Director of Shilpa Medicare Limited. Mr. Bhutada joined Shilpa Medicare Limited in November 1987. He serves as the Director at Maia Phar ...
CEO Compensation Analysis
Compensation vs Market: Vishnukanth's total compensation ($USD994.87K) is above average for companies of similar size in the Indian market ($USD358.82K).
Compensation vs Earnings: Vishnukanth's compensation has been consistent with company performance over the past year.
|MD & Director||no data||₹74.74m||11.56% ₹4.9b|
|VP of Technical & Whole-time Director||0.75yr||no data||0.034% ₹14.5m|
|Independent Director||1.25yrs||no data||no data|
|Independent Director||10.33yrs||₹20.00k||0.24% ₹103.0m|
|Independent Director||0.67yr||no data||no data|
|Non-Executive Chairman||no data||₹20.00k||3.77% ₹1.6b|
|Independent Director||12.08yrs||₹20.00k||0.031% ₹13.2m|
|Non-Executive Director||3.58yrs||no data||no data|
|Independent Director||1.25yrs||no data||no data|
Experienced Board: SHILPAMED's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Shilpa Medicare Limited's company bio, employee growth, exchange listings and data sources
- Name: Shilpa Medicare Limited
- Ticker: SHILPAMED
- Exchange: NSEI
- Founded: 1987
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹42.133b
- Shares outstanding: 81.53m
- Website: https://www.vbshilpa.com
- Shilpa Medicare Limited
- Shilpa House
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|530549||BSE (Mumbai Stock Exchange)||Yes||Equity Shares||IN||INR||Jul 1995|
|SHILPAMED||NSEI (National Stock Exchange of India)||Yes||Equity Shares||IN||INR||Jul 1995|
|530549||BSE (Mumbai Stock Exchange)||INR1||IN||INR||Nov 2015|
|SHILPAMED||NSEI (National Stock Exchange of India)||INR1||IN||INR||Nov 2015|
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells generic active pharmaceutical ingredients (APIs) and formulations in India, the United States, Europe, and internationally.. It offers active pharmaceutical ingredients and bulk drug intermediates for oncology and other therapeutic areas; and formulations, new drug delivery systems, peptides/biotech products, specialty chemicals, etc. The company also provides contract manufacturing of various dosage forms, such as tablets, capsules, liquid injections, lyophilized injectables, and sterile dry powder injectables. It is also involved in the generation and sale of wind power. Shilpa Medicare Limited was founded in 1987 and is headquartered in Raichur, India.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/10 13:01|
|End of Day Share Price||2020/07/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.